EWM
DNLI icon

Edge Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Edge Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$2K – 487
2020
Q2 		$2K Hold
100
– – ﹤0.01% 608
2020
Q1 		$2K Buy
+100
New +$2.09K ﹤0.01% 541

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edge Wealth Management's DNLI Position: Q3 2020 in Review

Edge Wealth Management sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 100 shares — an estimated $2K sold.

Edge Wealth Management first reported a position in DNLI in Q1 2020 and held it in 2 quarters. The position peaked at $2K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Edge Wealth Management reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Edge Wealth Management sold 100 Denali Therapeutics shares in Q3 2020, an estimated $2K.
  • Edge Wealth Management first reported a position in Denali Therapeutics in Q1 2020 and held it in 2 quarters.
  • Edge Wealth Management's Denali Therapeutics position peaked at $2K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Edge Wealth Management's 13F filing for Q3 2020, filed 21 Oct 2020.